Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S, Bamias A, Casper J, Negrier S, Sella A, Staehler M, Tarazi J, Felici A, Rosbrook B, Jardinaud-Lopez M, Escudier B. Bracarda S, et al. Among authors: rosbrook b. Clin Genitourin Cancer. 2019 Jun;17(3):e689-e703. doi: 10.1016/j.clgc.2019.03.017. Epub 2019 Apr 1. Clin Genitourin Cancer. 2019. PMID: 31072748 Free article. Clinical Trial.
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Rini BI, et al. Among authors: rosbrook b. Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531811
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Rini BI, et al. Among authors: rosbrook b. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Motzer RJ, et al. Among authors: rosbrook b. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH. Infante JR, et al. Among authors: rosbrook b. Cancer. 2013 Jul 15;119(14):2555-63. doi: 10.1002/cncr.28112. Epub 2013 Apr 19. Cancer. 2013. PMID: 23605883 Free article. Clinical Trial.
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF. Bendell JC, et al. Among authors: rosbrook b. Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001. Clin Colorectal Cancer. 2013. PMID: 24188685 Clinical Trial.
68 results